These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29872499)

  • 1. Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.
    Guffanti F; Fratelli M; Ganzinelli M; Bolis M; Ricci F; Bizzaro F; Chilà R; Sina FP; Fruscio R; Lupia M; Cavallaro U; Cappelletti MR; Generali D; Giavazzi R; Damia G
    Oncotarget; 2018 May; 9(37):24707-24717. PubMed ID: 29872499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts.
    Guffanti F; Alvisi MF; Caiola E; Ricci F; De Maglie M; Soldati S; Ganzinelli M; Decio A; Giavazzi R; Rulli E; Damia G
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations.
    Ganzinelli M; Mariani P; Cattaneo D; Fossati R; Fruscio R; Corso S; Ricci F; Broggini M; Damia G
    Eur J Cancer; 2011 May; 47(7):1086-94. PubMed ID: 21216588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial structural alterations in ovarian cancer patient-derived xenografts resistant to cisplatin.
    Ricci F; Corbelli A; Affatato R; Chilà R; Chiappa M; Brunelli L; Fruscio R; Pastorelli R; Fiordaliso F; Damia G
    Am J Cancer Res; 2021; 11(5):2303-2311. PubMed ID: 34094686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
    Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
    Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
    Meng CF; Dai DQ; Guo KJ
    Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer.
    Ricci F; Guffanti F; Affatato R; Brunelli L; Roberta P; Fruscio R; Perego P; Bani MR; Chiorino G; Rinaldi A; Bertoni F; Fratelli M; Damia G
    Am J Cancer Res; 2020; 10(2):572-580. PubMed ID: 32195028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.
    Notaro S; Reimer D; Fiegl H; Schmid G; Wiedemair A; Rössler J; Marth C; Zeimet AG
    BMC Cancer; 2016 Aug; 16():589. PubMed ID: 27485273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.
    Decio A; Cesca M; Bizzaro F; Porcu L; Bettolini R; Ubezio P; Taraboletti G; Belotti D; Giavazzi R
    Clin Exp Metastasis; 2015 Oct; 32(7):647-58. PubMed ID: 26185056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch repair and treatment resistance in ovarian cancer.
    Helleman J; van Staveren IL; Dinjens WN; van Kuijk PF; Ritstier K; Ewing PC; van der Burg ME; Stoter G; Berns EM
    BMC Cancer; 2006 Jul; 6():201. PubMed ID: 16879751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of molecular methodologies to assess PALB2 expression in sporadic breast cancer.
    Poumpouridou N; Acha-Sagredo A; Goutas N; Vlachodimitropoulos D; Chatziioannidou I; Lianidou E; Liloglou T; Kroupis C
    Clin Biochem; 2016 Feb; 49(3):253-9. PubMed ID: 26526077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
    Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    Fleming ND; Agadjanian H; Nassanian H; Miller CW; Orsulic S; Karlan BY; Walsh CS
    Cancer; 2012 Feb; 118(3):689-97. PubMed ID: 21751198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.
    Colombo PE; du Manoir S; Orsett B; Bras-Gonçalves R; Lambros MB; MacKay A; Nguyen TT; Boissière F; Pourquier D; Bibeau F; Reis-Filho JS; Theillet C
    Oncotarget; 2015 Sep; 6(29):28327-40. PubMed ID: 26334103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
    Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
    Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
    Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
    Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.